Skip to content

← All answered questions

Can Your LDL Cholesterol Be Too Low?

Inside this episode

The video’s narration, chapter by chapter, with stills from the video and every source at the end.

The short version

It's understandable that a number that low feels unsettling. Here's the short version. In studies of up to about eight years, very low LDL on these drugs hasn't shown a clear safety problem, though there's no lifetime data, and a lab's 10 may not be exact. On average, the doctor's plan gives back part of the drop; stopping both pills gives back much more. We found no outcome trial of evolocumab used instead of a statin.

Is an LDL of 10 too low?

In the trial's open extension, some people stayed on evolocumab over eight years; about a quarter averaged below 20 early on. Lower LDL wasn't linked to more cancer, cataracts, diabetes, memory problems or brain bleeds, and a memory-testing study matched placebo. The limits: these were mostly men around 60 with heart or artery disease, also on statins, and there's no lifetime data.

From the video: VERY LOW LDL: WHAT THE TRIALS FOUND, Gaba et al., Circulation 2023 (FOURIER-OLE). Europe PMC record, Up to ~8.6 years of follow-up, 2.2 years randomized, then an open, extension with no placebo group, Memory tests, no different from placebo, (randomized; 1,204 people, 19 months), Similar drug (alirocuma — Very low LDL: what the trials found. Gaba et al., Circulation 2023 (FOURIER-OLE). Europe PMC record

And the 10 itself may not be exact. Labs usually calculate LDL with a formula. In US lab data, when it read under 15, an ultracentrifuge test found a median of 29 points more, mostly with high triglycerides. In trial samples with normal triglycerides, it was only a few points off. And with high Lp(a), a mostly inherited cousin of LDL, part of the reported LDL is really Lp(a) cholesterol.

Cut back, or stop the pills?

In trials, rosuvastatin 10 milligrams lowered LDL only a few percentage points less than 20. Ezetimibe added to a statin cut roughly another fifth, and evolocumab about 55 to 65 percent, with or without a statin. Each removes a share of what's left, so on average, stopping both pills gives back far more than the doctor's plan.

From the video: TYPICAL TRIAL AVERAGES, NOT A FORECAST, Now, Rosuvastatin 20 mg, Ezetimibe, Evolocumab, Doctor’s plan, Rosuvastatin 10 mg, Ezetimibe, Evolocumab, Stop both pills, Rosuvastatin, Ezetimibe, Evolocumab, Typical LDL fall in trials, from each study’s starting level — Typical trial averages, not a forecast

Does evolocumab protect on its own? Its outcome trials added it to other treatment. In VESALIUS-CV, in people with significant plaque or high-risk diabetes but no heart attack or stroke, mostly on statins, first major events fell from about 8 to 6 in 100 over five years. We found no outcome trial of evolocumab used instead of a statin.

From the video: EVOLOCUMAB ON ITS OWN?, Bohula et al., NEJM 2026. Europe PMC record, First heart attack, ischemic stroke or, coronary death, 5 years, Placebo, 8.0%, Evolocumab, 6.2%, Added to usual cholesterol treatment, (mostly statins, per the trial team’s reports), No outcome trial found of evolocumab, instead of a — Evolocumab on its own? Bohula et al., NEJM 2026. Europe PMC record

And statins? Across many trials, benefit tracked how far LDL fell, for statins and similar-acting treatments. Statins also lower an inflammation marker, but whether that adds protection is unproven: evolocumab didn't lower it and still cut events. Statins don't lower Lp(a); studies disagree on whether they nudge it up; evolocumab cut it by about a quarter.

How do doctors set a target?

Summaries of the 2026 US guideline describe goals under 70 for high risk, and under 55 for very high risk, mostly after a heart attack or stroke, and for a heart-artery calcium score of 1,000 or more. An early family history and high Lp(a) count as risk boosters in borderline or intermediate cases. None of those summaries mention a lower limit, or cutting back because LDL is very low. The decision is theirs and their clinician's.

From the video: HOW LDL GOALS ARE SET (US, 2026), 0, 20, 40, 55, 70, 100, mg/dL LDL, under 100: borderline or intermediate risk, under 70: high risk, under 55: very high risk, floor?, none found, Very high risk: mostly after a heart attack or stroke — How LDL goals are set (US, 2026). 2026 ACC/AHA multisociety guideline, as described by Sabouret 2026, Carlson 2026, Syed 2026 (text not reviewed

Before you go: the rosuvastatin and Repatha labels say not to stop them without talking to your prescriber, and after any change, a repeat test weeks later helps show where LDL lands. Chest pain, or sudden weakness or trouble speaking: call nine-one-one right away.

From the video: BEFORE YOU GO, Don’t stop them on your own, Rosuvastatin label: “Do not change your dose or stop … without talking to your, healthcare provider, even if you are feeling well.”, Repatha label: “Do not stop using REPATHA without talking with your healthcare provider.”, After any change: a repeat lipid tes — Before you go. CDC heart attack (Oct 2024) and stroke (May 2026) pages, free at cdc.gov. Source: CDC; no CDC endorsement implied

Sources

32 sources cited in the video, in the order they come up.

More answered questions